A Survey of the European Association of Bronchology and Interventional Pulmonology (EABIP)

Publisher Copyright: © Copyright 2017 S. Karger AG, Basel. All rights reserved.Background: Airway stenting (AS) commenced in Europe circa 1987 with the first placement of a dedicated silicone airway stent. Subsequently, over the last 3 decades, AS was spread throughout Europe, using different insertion techniques and different types of stents. Objectives: This study is an international survey conducted by the European Association of Bronchology and Interventional Pulmonology (EABIP) focusing on AS practice within 26 European countries. Methods: A questionnaire was sent to all EABIP National Delegates in February 2015. National delegates were responsible for obtaining precise and objective data regarding the current AS practice in their country. The deadline for data collection was February 2016. Results: France, Germany, and the UK are the 3 leading countries in terms of number of centres performing AS. These 3 nations represent the highest ranked nations within Europe in terms of gross national income. Overall, pulmonologists perform AS exclusively in 5 countries and predominately in 12. AS is performed almost exclusively in public hospitals. AS performed under general anaesthesia is the rule for the majority of institutions, and local anaesthesia is an alternative in 9 countries. Rigid bronchoscopy techniques are predominant in 20 countries. Amongst commercially available stents, both Dumon and Ultraflex are by far the most commonly deployed. Finally, 11 countries reported that AS is an economically viable activity, while 10 claimed that it is not. Conclusion: This EABIP survey demonstrates that there is significant heterogeneity in AS practice within Europe. Therapeutic bronchoscopy training and economic issues/reimbursement for procedures are likely to be the primary reasons explaining these findings.publishersversionpublishe

Current Practice of Airway Stenting in the Adult Population in Europe: A Survey of the European Association of Bronchology and Interventional Pulmonology (EABIP)

Background: Airway stenting (AS) commenced in Europe circa 1987 with the first placement of a dedicated silicone airway stent. Subsequently, over the last 3 decades, AS was spread throughout Europe, using different insertion techniques and different types of stents. Objectives: This study is an international survey conducted by the European Association of Bronchology and Interventional Pulmonology (EABIP) focusing on AS practice within 26 European countries. Methods: A questionnaire was sent to all EABIP National Delegates in February 2015. National delegates were responsible for obtaining precise and objective data regarding the current AS practice in their country. The deadline for data collection was February 2016. Results: France, Germany, and the UK are the 3 leading countries in terms of number of centres performing AS. These 3 nations represent the highest ranked nations within Europe in terms of gross national income. Overall, pulmonologists perform AS exclusively in 5 countries and predominately in 12. AS is performed almost exclusively in public hospitals. AS performed under general anaesthesia is the rule for the majority of institutions, and local anaesthesia is an alternative in 9 countries. Rigid bronchoscopy techniques are predominant in 20 countries. Amongst commercially available stents, both Dumon and Ultraflex are by far the most commonly deployed. Finally, 11 countries reported that AS is an economically viable activity, while 10 claimed that it is not. Conclusion: This EABIP survey demonstrates that there is significant heterogeneity in AS practice within Europe. Therapeutic bronchoscopy training and economic issues/reimbursement for procedures are likely to be the primary reasons explaining these findings. (C) 2017 S. Karger AG, Base

Pilot feasibility study of transbronchial needle forceps: a new tool for obtaining histology samples from mediastinal subcarinal lymph nodes

BACKGROUND: Cutting transbronchial histology needles to obtain tissue cores from hilar/mediastinal lymph nodes or masses adjacent to the tracheobronchial tree are able to provide adequate histology tissue samples in only 38% to 78% of cases. The aim of this pilot study was to evaluate the efficacy and safety of a new instrument developed to obtain a fragment of a tissue for histologic diagnosis of enlarged subcarinal lymph nodes.METHODS: The transbronchial needle forceps (TBNF) is a sampling instrument that combines the characteristics of a needle (beveled tip for penetrating through the bronchial wall) with that of a forceps (2 serrated jaws for grasping the biopsy). The external diameter of the needle forceps is 1.5mm.RESULTS: Fourteen patients (11 male, 3 female; mean age: 51y) with subcarinal lymph node enlargement greater than 2cm in short axis were included in this pilot study. TBNF provided tissue for histologic diagnosis in 8 patients (57.1%). In 4 patients (28.5%) TBNF could not be inserted through the bronchial wall. For patients in whom it was possible to insert the TBNF, a tissue core adequate for histologic examination was obtained in 9 (90%) and a diagnosis in 8 (80%) (non-small-cell lung cancer in 3, sarcoidosis in 2, small cell lung cancer in 1, tuberculosis in 1, and Hodgkin lymphoma in 1). No clinically significant procedure-related complications were encountered.CONCLUSIONS: This study demonstrates that, when insertion through the bronchial wall is possible, TBNF safely provides diagnostic histologic specimens of subcarinal lymphadenopathy in a large percentage of cases

Stenting right main bronchus with montgomery T tube for upper lobe ventilation

The involvement of the right main bronchus (RMB) along with the upper lobe bronchus and bronchus intermedius by malignant tumor is frequently encountered. However, the use of a stent for palliation of airway stenosis of the RMB might obstruct upper lobe orifice and pose complications such as atelectasis or recurrent pneumonia. We report the use of modified Montgomery T tube in a 78-year-old man with neoplasm of the RMB by placing the tracheostomy arm of the T tube in the upper lobe bronchus to maintain its patency

Immunohistochemistry for Claudin-4 and BAP1 in the Differential Diagnosis between Sarcomatoid Carcinoma and Sarcomatoid Mesothelioma

(1) Background. In the differential diagnosis between sarcomatoid carcinoma (SC) and sarcomatoid mesothelioma (SM), we aimed to investigate the role of Claudin-4 and BAP1, a panel recently used to distinguish conventional carcinoma from epithelioid mesothelioma. (2) Methods. We collected 41 surgical pleural biopsies of SM, 46 surgical resections of SC from different sites and 49 pleural biopsies of normal/hyperplastic mesothelium. All the cases were tested for Claudin-4 and BAP1 using immunohistochemistry. The statistical calculations of the sensitivity, specificity and positive and negative predictive values were performed. (3) Results: Claudin-4 was negative in 41/41 SMs, while it was positive in 18/36 (50.1%) SCs (eight diffusely, 10 focally) within their sarcomatous component. BAP1 was lost in 23/41 SMs, while it was regularly expressed in 46/46 SCs. All the cases of the normal/hyperplastic mesothelium were negative for Claudin-4 and retained the regular expression of BAP1. The Claudin-4 expression was useful for detecting SC (sensitivity, 39.1%; specificity, 100%) and the BAP1 loss was useful for diagnosing SM (sensitivity, 56.1%; specificity, 100%). (4) Conclusions. The staining for Claudin-4 and BAP1 exhibited a low/moderate sensitivity in diagnosing SC and SM (39.1% and 56.1%, respectively), but a very high specificity (100%). Claudin-4 was expressed only in SC and BAP1 loss was noted only in SM